Trade Names:Valcyte- Tablets 450 mg- Powder for oral solution 50 mg/mL
Valganciclovir is a prodrug of ganciclovir, which inhibits cytomegalovirus (CMV) replication by inhibition of viral DNA synthesis.
Well absorbed from the GI tract. Bioavailability is approximately 60%. T max is approximately 1 to 3 h. When administered with high-fat meal, AUC increased 30% and C max increased 14%. Administer with food.
Valganciclovir is metabolized to ganciclovir. Protein binding of ganciclovir is approximately 1% to 2%. Vd of ganciclovir is approximately 0.703 L/kg.
Rapidly metabolized in the intestinal wall and liver to ganciclovir.
Major route of elimination is by renal excretion. The half-life is approximately 4 h (tablets).
Dosage reductions according to CrCl are required for valganciclovir.Hepatic Function Impairment
The safety and efficacy have not been studied in patients with hepatic impairment.Elderly
Pharmacokinetics have not been established in elderly patients.Children
Children produce similar exposure to adult patients.
Treatment of CMV retinitis in adult patients with AIDS; prevention of CMV disease in kidney, heart, and kidney-pancreas transplant adult patients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R−]); for the prevention of CMV disease in kidney and heart transplant pediatric patients at high risk.
Hypersensitivity to ganciclovir or valganciclovir.
PO 900 mg twice daily with food for 21 days. Following this induction phase, or in patients with inactive CMV retinitis, give 900 mg every day with food.Prevention of CMV Disease in Heart, Kidney, and Kidney-Pancreas TransplantationAdults
PO 900 mg every day with food, starting within 10 days of transplantation until 100 days posttransplantation.Prevention of CMV Disease in Kidney and Heart TransplantationChildren 4 mo to 16 yr of age
PO Dose is administered once daily starting within 10 days of transplantation until 100 days posttransplantation and is based on BSA and CrCl. All calculated doses should be rounded to the nearest 25 mg increment for the actual deliverable dose. If the calculated dose exceeds 900 mg, a maximum dose of 900 mg should be administered. See the following equation: Dose (mg) = 7 × BSA × CrCl (calculated using a modified Schwartz formula). î€
Where k = 0.45 for patients younger than 2 yr of age (note: k value is 0.45 instead of typical value 0.55); k = 0.55 for boys 2 to younger than 13 yr of age and for girls 2 to 16 yr of age; and k = 0.7 for boys 13 to 16 yr of age.Decreased Renal FunctionAdults Induction
PO 900 mg twice daily (CrCl 60 mL/min or more); 450 mg twice daily (CrCl 40 to 59 mL/min); 450 mg every day (CrCl 25 to 39 mL/min); 450 mg every 2 days (CrCl 10 to 24 mL/min); not recommended for CrCl less than 10 mL/min on hemodialysis.Maintenance
PO 900 mg/day (CrCl 60 mL/min or more); 450 mg every day (CrCl 40 to 59 mL/min); 450 mg every 2 days (CrCl 25 to 39 mL/min); 450 mg twice/wk (CrCl 10 to 24 mL/min); not recommended for CrCl less than 10 mL/min on hemodialysis.
Store at controlled room temperature (59° to 86°F). Store constituted solution under refrigeration (36° to 46°F) for no longer than 49 days.
Interaction studies have not been conducted; however, because valganciclovir is converted to ganciclovir, interactions associated with ganciclovir are expected to occur for valganciclovir.Didanosine
Plasma levels of didanosine may be increased, while didanosine may decrease levels of ganciclovir. Didanosine dosage adjustment may be needed.Mycophenolate mofetil
In patients with normal renal function, no pharmacokinetic interaction was observed. However, closely monitor patients with renal function impairment because concentrations of ganciclovir and mycophenolate metabolites may be increased.Myelosuppressive drugs, irradiation
Risk of cytopenia may be increased. Use with caution.Nephrotoxic drugs
Risk of renal failure may be increased. Use with cautionProbenecid
May reduce ganciclovir renal Cl and increase ganciclovir serum levels.Trimethoprim
Ganciclovir renal Cl may be decreased while the half-life may be increased.Zidovudine
Both ganciclovir and zidovudine can cause anemia and neutropenia. Zidovudine dosage adjustment may be needed.
None well documented.
Hypertension (18%); hypotension (at least 5% or selected serious adverse reaction).
Tremors (28%); headache (22%); insomnia (20%); peripheral neuropathy (9%); paresthesia (8%); agitation, confusion, convulsions, depression, dizziness, fatigue, hallucinations, psychosis (at least 5% or selected serious adverse reactions).
Acne, dermatitis, pruritus (at least 5% or selected serious adverse reactions).
Retinal detachment (15%); pharyngitis/nasopharyngitis, rhinorrhea (at least 5% or selected serious adverse reactions).
Diarrhea (41%); nausea (30%); vomiting (21%); abdominal pain (15%); abdominal distention, ascites, constipation, dyspepsia (at least 5% or selected serious adverse reactions).
Decreased CrCl, dysuria, renal impairment, UTI (at least 5% selected or serious adverse reactions).
Anemia (1% to 31%); thrombocytopenia (0% to 22%); neutropenia (3% to 19%); aplastic anemia, bone marrow depression, pancytopenia (at least 5% or selected serious adverse reactions).
Abnormal hepatic function (at least 5% or selected serious adverse reactions).
Decreased appetite, dehydration, hyperglycemia, hyperkalemia, hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia (at least 5% or selected serious adverse reactions).
Arthralgia, back pain, limb pain, muscle cramps (at least 5% or selected serious adverse reactions).
Cough, dyspnea, pleural effusion, upper respiratory tract infection, (at least 5% or selected serious adverse reactions).
Pyrexia (31%); graft rejection (24%); catheter-related infections (3%); edema, hypersensitivity, increased wound drainage, local and systemic infections and sepsis, pain, peripheral edema, postoperative pain and complications, weakness, wound dehiscence, wound infection and complications (at least 5% or selected serious adverse reactions).
Toxicity includes anemia, granulocytopenia, and thrombocytopenia. In animal studies, ganciclovir was carcinogenic, teratogenic, and caused aspermatogenesis.
Monitor CBC with differential and platelet counts frequently, especially in patients in whom ganciclovir or other nucleoside analogues have previously resulted in leukopenia, or in whom neutrophil counts are less than 1,000 cells/mcL at the beginning of treatment. Monitor serum creatinine or CrCl values carefully to allow for dosage adjustments in renally impaired patients.
Category C .
Undetermined; however, the CDC recommends that HIV-infected mothers not breast-feed infants to avoid risk of HIV transmission.
Safety and efficacy have been established in children 4 mo to 16 yr of age for the prevention of CMV disease in kidney and heart transplant patients. Safety and efficacy have not been established in children for the prevention of CMV disease in liver transplant patients, solid organ transplants other than those indicated, or for the treatment of congenital CMV disease.
Because elderly patients are more likely to have decreased renal function, take care in dose selection.
Use with caution and adjust dosage.
Safety and efficacy have not been studied in patients with hepatic impairment.
If broken or crushed tablet comes in contact with skin or mucus membranes, wash thoroughly with soap and water and rinse eyes thoroughly with plain water.
Severe leukopenia, neutropenia, bone marrow depression, and aplastic anemia have been reported; therefore, use with caution in patients with preexisting cytopenias, or those who have received or are receiving myelosuppressive drugs or irradiation.
Acute renal failure my occur in elderly patients, patients receiving potential nephrotoxic agents, and patients without adequate hydration.
Abdominal pain, acute renal failure, bone marrow depression, convulsion, diarrhea, elevated creatinine, generalized tremor, granulocytopenia, hepatitis, leukopenia, liver function disorder, medullary aplasia, neutropenia, pancytopenia, renal toxicity, worsening of hematuria, vomiting.
Copyright © 2009 Wolters Kluwer Health.